Altogether, these results indicate that two completely independent strategies, one based on the functional analysis of EGR2, a critical target of EWSR1-FLI1, and the other based on an agnostic screening of Ewing cells’ pharmacological vulnerabilities, point out the MVA pathway as a major dependency in Ewing sarcoma. This evidence concerns the gene FLI1 and Ewing sarcoma.